Navigation Links
SPO Medical Retains American Capital Ventures for Investor Relations Services

NEW YORK, April 17 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that it has retained the services of American Capital Ventures (ACV), a leading provider of comprehensive investor relations services to the small cap community, as an investor relations consultant.

Michael Braunold, President and Chief Executive Officer of SPO Medical commented, "As we continue to grow our revenues and enhance our distribution base, it has become increasingly important to reach out to the investment community. Our goal is to inform current and prospective investors of our financial prospects and the value proposition offered by our product pipeline and strategy." Mr. Braunold continued, "Our portable devices and new consumer applications will appeal to an ever growing number of markets globally. This is a powerful message we need to convey to investors and American Capital Ventures has a proven track record assisting small cap companies in communicating their message to the investor community."

Howard Gostfrand, President of American Capital Ventures, commented, "SPO Medical has positioned itself well in the burgeoning medical field of non-invasive devices. They have clearly laid the groundwork with key investments and strategic partnerships that have been delivering tangible results. Achieving revenues of $5 million in 2007 after only three years, and with an impressive product channel, SPOM is a perfect example of a promising undiscovered small cap company worth an investor's consideration."

About SPO Medical

SPO Medical (SPOM) is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

About American Capital Ventures (ACV)

American Capital Ventures (ACV) is a boutique investor relations firm founded on the principals of hard work, professionalism and integrity. Our company offers emerging growth companies a different, more comprehensive approach to investor relations. ACV delivers highly effective investor communications counsel in conjunction with developing tangible brokerage relationships for our clients. Our unique blend of creating awareness while effectively increasing a company's trading volume has allowed us to continually expand our business. Our goal is to allow management the ability to focus on their core business, while assisting them in communicating their message and develop their investor relationships.

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

SPO Medical Contact:

Michael Braunold, President & CEO, ,


ACV Contact:

Howard Gostfrand / David Sasso,

+1-305-918-7000, .

SOURCE SPO Medical Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atom Medical Adopts Masimo Rainbow SET Technology
2. NYU Medical Center Changes Name to Honor Chairman of Board & Wife
3. BioMS Medical to present at EQUITIES Conference
4. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target
8. SPO Medical to Conduct Live Investor Meeting on April 29, 2008
9. ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
10. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
11. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):